RxDoctor Payments Data

Ajitesh Rai, MD

Neurology · Alton, ILNPI 1205883097

Payments from drug & device makers

$7,922in general payments, 2019–2025

Across 425 payments — averaging $18.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Jazz Pharmaceuticals Inc.$695
  • Novartis$672
  • Supernus Pharmaceuticals, Inc.$538
  • UCB, Inc.$468
  • Harmony Biosciences LLC$285
  • plus $4K from 49 others

What the payments were for

  • Speaking & faculty fees$1081%
  • Food & beverage$7,64697%
  • Education$1672%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,922 in reported general payments places this provider in the 70th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois

Medicare billing

Part B allowed, 2024
$169,608
Medicare patients
633
Services billed
4,956

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XywavSodium,calcium,mag,pot Oxybate13$245,298
WakixPitolisant Hcl12$151,750
Gamunex-CImmune Globul G/Gly/Iga Avg 4636$132,583
SunosiSolriamfetol Hcl62$53,095
Modafinil198$11,588
BelsomraSuvorexant15$6,782
Armodafinil79$5,601
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine133$3,524
Divalproex Sodium42$2,961
Carbamazepine ErCarbamazepine23$2,224
Dimethyl Fumarate11$1,758
Levetiracetam60$1,647
Zolpidem Tartrate268$1,644
Memantine Hcl28$1,632
Pregabalin19$1,628

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Harmony Biosciences LLCWakix$285$151,75012 claims
Grifols USA, LLCGamunex-C$79$132,58336 claims
Axsome Therapeutics, Inc.Sunosi$172$53,09562 claims
Upsher-smith Laboratories LLCTopiramate$46$21832 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 790 neurology providers in Illinois.

Other neurology in Alton

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →